Search Results
Aug 25, 2026, 20:27 ET Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
CORP.Vector Science and Therapeutics Corp., headquartered in Mequon, Wisconsin, develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The Company's shares
More news about: Vector Sciences & Therapeutics
Aug 25, 2026, 18:00 ET Stowers scientists develop a new way to visualize what AI models learn from DNA -- and discover how to control what the models learn next
matters."Knowing that a variant sits in a transcription factor binding site or at a domain boundary, and which cell type it acts in, does not produce a drug. It does, however, propose a mechanism, and that can be very important for deciding what to do next."Ultimately, there is a solution to the problem,
More news about: Stowers Institute for Medical Research
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform,
More news about: Akeso, Inc.
Aug 25, 2026, 16:41 ET Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
Avilar Therapeutics, a company RA Capital helped establish later that year, used confidential information from those discussions to build a competing drug development program instead of pursuing a partnership with Yale.Biohaven licensed the MODA platform from Yale to develop and commercialize
More news about: Biohaven Ltd.
Aug 25, 2026, 14:49 ET Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Ill., Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is
More news about: Abbott
Aug 25, 2026, 12:25 ET OmicsBank Raises $2.25M to Expand Clinical Data Infrastructure Globally for Healthcare, Life Sciences, and Frontier AI Labs
greater diversity to drug development and healthcare AI.SAN FRANCISCO, Aug. 25, 2026 /PRNewswire/ -- OmicsBank, a clinical data infrastructure company connecting fragmented hospital data for drug development and healthcare
More news about: Redesign Health; OmicsBank
Aug 25, 2026, 12:25 ET Professor Sarfaraz Niazi of Washington State University Files FDA Citizen Petition Seeking New Pathway to Make High-Cost Medicines More Accessible Worldwide
ConsequencesAlthough the Citizen Petition asks the U.S. Food and Drug Administration to act under American law, its implications may extend far beyond the United States.The regulatory standards established by the Food and Drug Administration (FDA) markedly shape drug development strategies, investment choices, and
More news about: Professor Sarfaraz K. Niazi
Aug 25, 2026, 12:00 ET CLERIVY Brings a K-Beauty Take on Pimple Patches to Amazon.com
[email protected] Required noticesCLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The
More news about: CLERIVY
Aug 25, 2026, 11:12 ET Cambrex High Point achève les inspections préalables à l'autorisation menées par la FDA, la PMDA et la TGA, renforçant ainsi ses capacités de production commerciale
avoir achevé avec succès trois inspections préalables à l'autorisation (PAI) menées sur son site de High Point, en Caroline du Nord, par la Food and Drug Administration (FDA) américaine, l'Agence japonaise des produits pharmaceutiques et des dispositifs médicaux (PMDA) et l'Administration australienne
More news about: Cambrex
Aug 25, 2026, 10:31 ET Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
including Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others, and innovative drug delivery approaches that address unmet clinical needs.LAS VEGAS, Aug.
More news about: DelveInsight Business Research, LLP
Aug 25, 2026, 10:15 ET Peptide Synthesis Market worth $1.54 billion by 2031 - Exclusive Report by MarketsandMarkets™
purification systems, and analytical instruments. Rising demand for custom peptides, modified peptides, long peptides, and peptide libraries used in drug discovery, assay development, biomarker research, and antibody production is also driving adoption. Improvements in automated solid-phase peptide synthesis,
More news about: MarketsandMarkets
Aug 25, 2026, 10:03 ET Stella Health Insurance Agency Expands Agent Offerings through Integrity's Proven AI-Powered Solutions
sales, the agency's licensed professionals help beneficiaries navigate plan options on their terms, with a thorough focus on doctor access, prescription drug coverage and overall plan fit. Widely regarded as a trusted resource by physician offices, medical groups and community liaisons throughout Southern
More news about: Integrity
Aug 25, 2026, 10:00 ET Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrome
Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to MZ-1866, Mahzi's investigational gene therapy for the treatment of Pitt
More news about: MAHZI Therapeutics
Aug 25, 2026, 10:00 ET Recent Food Recalls Raise Health Concerns, SignatureCare Emergency Center ER Physician Urges Caution -- Especially for Children
involving shell eggs. The recalled eggs were distributed to retailers and food-service customers in Texas, Oklahoma, and Louisiana.The U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) have linked the recalled eggs to a multistate Salmonella outbreak. They are
More news about: SignatureCare Emergency Centers
Aug 25, 2026, 10:00 ET Leading heart doctor Andrew Ambrosy warns that low-dose aspirin may harm - more than help - healthy adults
advised. "Yes, these patients should be on a medicine that keeps blood cells from clumping, but they should speak with their doctor to find out which drug is right for them," the heart doctor said.For some patients, he noted, the anti-platelet medication clopidogrel (brand name Plavix) may be a
More news about: Andrew P. Ambrosy, MD, MPH
Aug 25, 2026, 10:00 ET U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
standard-of-care chemotherapy for first-line GEA. Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC, gastric (including GEJ) cancer, and esophageal cancer, as well as Orphan Drug designations from the European Medicines Agency for the treatment of BTC,
More news about: Jazz Pharmaceuticals plc
Aug 25, 2026, 09:27 ET Israel Cancer Research Fund Announces $5.35 Million in New Cancer Research Grants for 2026 to 2027
Roichman, PhD, Bar Ilan University, Career Development AwardDeciphering Diet and Microbiome Interactions that Shape Anti-Cancer Drug Pharmacokinetics and EfficacyICRF's Career Development Awards help emerging Israeli scientists establish independent research careers. Roichman,
More news about: Israel Cancer Research Fund
Aug 25, 2026, 09:15 ET /C O R R E C T I O N -- Akeso, Inc./
("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation
More news about: Akeso, Inc.
Aug 25, 2026, 09:00 ET ASRC Federal Selected to Modernize and Operate Enterprise IT for U.S. Drug Enforcement Administration
Company subsidiary awarded a $75 million contract by U.S. Department of Justice Drug Enforcement Administration (DEA) supporting software development, testing and requirement analysis of new and existing applications on the agency's Concorde enterprise information technology platform.Company
More news about: ASRC Federal
Aug 25, 2026, 08:51 ET Cambrex、ハイポイント施設におけるFDA、PMDA、TGAによる承認前査察を完了し、商業生産体制を強化
ニュージャージー州イーストラザフォード, 2026年8月25日 /PRNewswire/ -- 世界をリードする医薬品開発製造受託機関（CDMO）であるCambrexは、ノースカロライナ州ハイポイントにある同社施設において、U.S. Food and Drug Administration（FDA）、 日本のPharmaceuticals and Medical Devices Agency (PMDA)、およびオーストラリアのTherapeutic Goods Administration (TGA)による3件の承認前査察（PAI）が、同社のノース
More news about: Cambrex
Aug 25, 2026, 08:45 ET WuXi Biologics Reports Strong Profitable Growth in H1 2026
Win-the-Molecule competitiveness and enable strong growth of biosimilar programsWell-positioned to capture incremental demand from digital advances in drug discovery and next-gen therapeutic platformsHONG KONG, Aug. 25, 2026
More news about: WuXi Biologics
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
steadily; as of July 31, 2026, cumulative enrollment exceeded 1,000 cases, reaching over 50% of the planned enrollment target. HT001, an investigational drug for Parkinson's disease, has initiated Phase 1 clinical trials in Australia. Parallel work is underway on the clinical deployment of magnetic-resonance-guided
More news about: Fosun Pharma
Aug 25, 2026, 08:30 ET Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings
More news about: Nektar Therapeutics
Aug 25, 2026, 08:15 ET National Recovery Month: New Federal Data Reveal Substance Use Treatment Gap
2025 National Survey on Drug Use and Health showing that only 16% of the 47.2 million Americans age 12 or older who needed substance use treatment in 2025 received it. Board-certified
More news about: Choose Freedom, LLC
Aug 25, 2026, 08:06 ET Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)
U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CK0803 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The designation was granted under Section 506(b) of the Federal Food, Drug, and Cosmetic Act in connection with the company's Investigational New Drug (IND) application
More news about: Cellenkos, Inc.